<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Shin Nippon Biomedical Laboratories, Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/shin-nippon-biomedical-laboratories-ltd</link>
    <description>Latest news and press releases for Shin Nippon Biomedical Laboratories, Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 05 Nov 2025 13:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/shin-nippon-biomedical-laboratories-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d613ecbeedb30cb6fbc79c.webp</url>
      <title>Shin Nippon Biomedical Laboratories, Ltd.</title>
      <link>https://6ix.com/company/shin-nippon-biomedical-laboratories-ltd</link>
    </image>
    <item>
      <title>Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache</title>
      <link>https://6ix.com/company/shin-nippon-biomedical-laboratories-ltd/news/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-of-use-and-satisfaction-with-sts101-dihydroergotamine-nasal-powder-atzumitm-in-headache</link>
      <guid isPermaLink="true">https://6ix.com/company/shin-nippon-biomedical-laboratories-ltd/news/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-of-use-and-satisfaction-with-sts101-dihydroergotamine-nasal-powder-atzumitm-in-headache</guid>
      <pubDate>Wed, 05 Nov 2025 13:00:00 GMT</pubDate>
      <description>Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) are dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. STS101 is the only product to combine Satsuma&apos;s proprietary SMART™ (Simple MucoAdhesive Release Technology) with an easy-to-use, easy-to carry nasal delivery device.</description>
    </item>
    <item>
      <title>Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society&apos;s 67th Annual Scientific Meeting</title>
      <link>https://6ix.com/company/shin-nippon-biomedical-laboratories-ltd/news/satsuma-pharmaceuticals-and-snbl-announce-four-abstracts-to-be-presented-at-the-american-headache-societys-67th-annual-scientific-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/shin-nippon-biomedical-laboratories-ltd/news/satsuma-pharmaceuticals-and-snbl-announce-four-abstracts-to-be-presented-at-the-american-headache-societys-67th-annual-scientific-meeting</guid>
      <pubDate>Thu, 19 Jun 2025 13:00:00 GMT</pubDate>
      <description>Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that four abstracts describing efficacy and safety results from Satsuma&apos;s Phase 3 clinical study program were selected for presentation at the American Headache Society&apos;s (AHS) 67th Annual Scientific Meeting. The 2025 meeting</description>
    </item>
    <item>
      <title>Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine</title>
      <link>https://6ix.com/company/shin-nippon-biomedical-laboratories-ltd/news/satsuma-pharmaceuticals-announces-us-fda-approval-for-atzumitm-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine</link>
      <guid isPermaLink="true">https://6ix.com/company/shin-nippon-biomedical-laboratories-ltd/news/satsuma-pharmaceuticals-announces-us-fda-approval-for-atzumitm-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine</guid>
      <pubDate>Thu, 01 May 2025 00:00:00 GMT</pubDate>
      <description>Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that the U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™(dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi</description>
    </item>
  </channel>
</rss>